BUZZ-Akebia Therapeutics 在美国食品药品管理局的贫血药物试验受挫后暴跌

路透中文

Oct 29, 2025

BUZZ-Akebia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 在<a href="https://laohu8.com/S/USFD">美国食品</a>药品管理局的贫血药物试验受挫后暴跌

10月28日 - ** 药物开发商 Akebia Therapeutics AKBA.O 的股票在延时交易中下跌 29% 至 2.17 美元

** 该公司表示，它将不会为其贫血药物Vafseo在 (link) 更广泛的美国标签。

** Akebia未能与美国FDA就一项针对非透析慢性肾病患者的试验设计方案达成协议

** FDA 的反馈意见表明，该试验需要更多的患者，因此成本过高且耗时过长 - AKBA

** 美国食品和药物管理局于 2024 年批准 (link) Vafseo 用于治疗接受透析至少三个月的成人慢性肾病引起的贫血。

** 股价今年累计上涨 62

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579990176"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579990176\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579990176?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-29 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579990176","market":"us","top_or_hot":-1,"title":"BUZZ-Akebia Therapeutics 在美国食品药品管理局的贫血药物试验受挫后暴跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 在<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品管理局的贫血药物试验受挫后暴跌</title></head><body><p>\n<span>10月28日</span><span> - </span>** 药物开发商 Akebia Therapeutics <span>AKBA.O</span> 的股票在延时交易中下跌 29% 至 2.17 美元</p><p>** 该公司表示，它将不会为其贫血药物Vafseo在 (link) 更广泛的美国标签。</p><p>** Akebia未能与美国FDA就一项针对非透析慢性肾病患者的试验设计方案达成协议</p><p>** FDA 的反馈意见表明，该试验需要更多的患者，因此成本过高且耗时过长 - AKBA</p><p>** 美国食品和药物管理局于 2024 年批准 (<span>link</span>) Vafseo 用于治疗接受透析至少三个月的成人慢性肾病引起的贫血。</p><p>** 股价今年累计上涨 62</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Akebia Therapeutics 在美国食品药品管理局的贫血药物试验受挫后暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Akebia Therapeutics 在美国食品药品管理局的贫血药物试验受挫后暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-10-29 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 在<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品管理局的贫血药物试验受挫后暴跌</title></head><body><p>\n<span>10月28日</span><span> - </span>** 药物开发商 Akebia Therapeutics <span>AKBA.O</span> 的股票在延时交易中下跌 29% 至 2.17 美元</p><p>** 该公司表示，它将不会为其贫血药物Vafseo在 (link) 更广泛的美国标签。</p><p>** Akebia未能与美国FDA就一项针对非透析慢性肾病患者的试验设计方案达成协议</p><p>** FDA 的反馈意见表明，该试验需要更多的患者，因此成本过高且耗时过长 - AKBA</p><p>** 美国食品和药物管理局于 2024 年批准 (<span>link</span>) Vafseo 用于治疗接受透析至少三个月的成人慢性肾病引起的贫血。</p><p>** 股价今年累计上涨 62</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nL4T3W92KB:1","article_id":"2579990176","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579990176","pubTimestamp":1761686178,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"10月28日 - ** 药物开发商 Akebia Therapeutics AKBA.O 的股票在延时交易中下跌 29% 至 2.17 美元** 该公司表示，它将不会为其贫血药物Vafseo在  更广泛的美国标签。** Akebia未能与美国FDA就一项针对非透析慢性肾病患者的试验设计方案达成协议** FDA 的反馈意见表明，该试验需要更多的患者，因此成本过高且耗时过长 - AKBA** 美国食品和药物管理局于 2024 年批准  Vafseo 用于治疗接受透析至少三个月的成人慢性肾病引起的贫血。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Akebia Therapeutics plummets after setback in FDA's anemia drug trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":0.9},"content_text":"BUZZ-Akebia Therapeutics 在美国食品药品管理局的贫血药物试验受挫后暴跌\n10月28日 - ** 药物开发商 Akebia Therapeutics AKBA.O 的股票在延时交易中下跌 29% 至 2.17 美元** 该公司表示，它将不会为其贫血药物Vafseo在 (link) 更广泛的美国标签。** Akebia未能与美国FDA就一项针对非透析慢性肾病患者的试验设计方案达成协议** FDA 的反馈意见表明，该试验需要更多的患者，因此成本过高且耗时过长 - AKBA** 美国食品和药物管理局于 2024 年批准 (link) Vafseo 用于治疗接受透析至少三个月的成人慢性肾病引起的贫血。** 股价今年累计上涨 62(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}